Breaking News
0

Alexza Pharmaceuticals: Teva Launches Adasuve, Alexza Raises $45M

By Edison Stock MarketsApr 01, 2014 02:27AM ET
www.investing.com/analysis/alexza-pharmaceuticals:-teva-launches-adasuve,-alexza-raises-$45m-208094
Alexza Pharmaceuticals: Teva Launches Adasuve, Alexza Raises $45M
By Edison   |  Apr 01, 2014 02:27AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Teva launches Adasuve, Alexza raises $45m

Adasuve (Staccato loxapine) was launched in the US by Teva in early March, at a price of $145/dose (above our previous forecast of $80/dose). Alexza Pharmaceuticals Inc (ALXA.O) also raised $45m in debt financing, which we estimate could potentially extend its funding runway to the stage where Adasuve-related revenues would sustainably generate positive free cash flow, thereby lessening financing risks. We now estimate 2018 global sales of $337m (up from $213m, previously), and increase our valuation to $9.06/share (vs $6.05, previously), strengthening the investment case.

Alexza Pharmaceuticals Inc Chart
Alexza Pharmaceuticals Inc Chart

Adasuve US price well ahead of previous guidance

Adasuve’s US launch price of $145/dose was above the $75-125 range previously estimated by Alexza management. The product was also granted a ‘C’ billing code for reimbursement by Centers for Medicare & Medicaid Services (CMS), which may help ease product reimbursement in outpatient settings and support adoption.

$45m financing extends Alexza’s financial flexibility

On 18 March, Alexza issued $45m in senior secured notes (bearing 12.25% pa interest) and five-year warrants to purchase 345,561 common shares at $0.01/share. Alexza expects the net proceeds of $41m will provide sufficient funds to maintain operations into 2015. Alexza can also draw down another $10m from its Teva loan facility. Hence, we project that both these sources of funds could enable the firm to reach the point in time (estimated in H216) where Adasuve-related royalty and milestone revenue from its partners should exceed Alexza’s operating costs, assuming R&D investments do not increase materially.


EU roll-out continues

Since January 2014, EU partner Ferrer launched Adasuve in Spain (triggering a $1m milestone payment to Alexza) and in Romania. Adasuve was introduced in Germany and Austria in H213 and further EU launches are expected in 2014 and 2015.


Valuation: rNPV of $145.4m represents upside

We calculate an rNPV for Adasuve and AZ-002 at $145.4m. Adding $14.2m in estimated net cash (at Q413) gives a $9.06 per share valuation for the firm. This offers significant upside to the current share price. We also do not specifically value the Staccato platform technology, which we believe can be extended into other pharmaceutical ingredients and provide further value-creation opportunities.

To Read the Entire Report Please Click on the pdf File Below

Alexza Pharmaceuticals: Teva Launches Adasuve, Alexza Raises $45M
 

Related Articles

Alexza Pharmaceuticals: Teva Launches Adasuve, Alexza Raises $45M

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email